Farglitazar
Alternative Names: GI-2570; GI-262570; GW 262570XLatest Information Update: 08 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Oxazoles
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 19 Aug 2021 Pharmacodynamics data of a phase II trial in Hepatic fibrosis presented at The International Liver Congress 2021 (ILC 2021)
- 19 Apr 2011 No development reported - Phase-II for Hepatic fibrosis in Australia, Canada, Czech Republic, Finland, Germany, Israel, Malaysia, New Zealand, Puerto Rico, Romania, Russia, Singapore, South Korea, Taiwan, USA (PO)
- 25 Oct 2001 Discontinued-III for Type-2 diabetes mellitus in United Kingdom (Unknown route)